Article: Appointments And Advancements.

Article: OBIT - GRAHAM, BURTON BOWLING
Roanoke Times & World News;  May 3, 2005 ;     216 words ...Burton Bowling Graham, 59, of Iron Gate, died Monday, May 2, 2005. Funeral service 2 p.m. Wednesday, May 4, 2005 in the Chapel of Arritt Funeral Home.

Article: Nasdaq Goes to Tokyo - But is Tokyo Ready? >BY Graham ...
Computergram International;  August 25, 1999 ;     700+ words ...Ordinarily, it takes twenty years for a company to go from start- up to flotation in Japan, compared to around four or five years for the average company floating on the US's hi-tech dominated Nasdaq market. But Masayoshi Son, the maverick founder and CEO of internet holding company Softbank Corp,

Article: APPOINTMENTS AND ADVANCEMENTS.(appointed Clive Kruckemeyer ...
BIOWORLD Today;  July 24, 2003 ;     700+ words ... ... Martin Wasserman to senior vice president of discovery research ... Warren, N.J., appointed Graham Burton senior vice president of regulatory affairs ... and Michael Vander Zwan vice president of quality assurance and ...

Article: EU orphan status for Celgene's Revlimid.(European Union)(Brief ...
Pharma Marketletter;  December 10, 2007 ;     700+ words ... ... around 165,000 people in the European Union, based on an estimated prevalence of 3.5 per 10,000. Graham Burton, senior vice president, global regulatory affairs and pharmacovigilance for Celgene Corp, said: "we continue to be encouraged ...

Article: FDA fast-track for Celgene's amrubicin.
Pharma Marketletter;  September 8, 2008 ;     668 words ... ... increasing focus on the clinical potential of Amrubicin as a treatment for small cell lung cancer," said Graham Burton, senior vice president, global regulatory affairs and pharmacovigilance at Celgene. "It further validates the considerable ...

Article: ODAC Panel Backs Celgene's Single Study Data On Revlimid.
BIOWORLD Today;  November 3, 2009 ;     700+ words ... ... responses and remissions, as well as marrow normalization and improvements. Those benefits, said Graham Burton, Celgene's senior vice president of regulatory affairs, are "evidence that Revlimid is having a disease-modifying effect ...

Article: ODAC PANEL BACKS CELGENE'S SINGLE STUDY DATA ON REVLIMID.
BIOWORLD Today;  September 15, 2005 ;     700+ words ... ... responses and remissions, as well as marrow normalization and improvements. Those benefits, said Graham Burton, Celgene's senior vice president of regulatory affairs, are "evidence that Revlimid is having a disease-modifying effect ...